The Wayback Machine - https://web.archive.org/web/20120119213554/http://en.wikipedia.org/wiki/Promethazine

Promethazine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Promethazine
Systematic (IUPAC) name
(RS)-N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a682284
Pregnancy cat. C(AU) C(US)
Legal status P (UK) -only (US)
(injection POM(UK))
Routes Oral, rectal, IV, IM, topical
Pharmacokinetic data
Bioavailability 88% absorbed but after first-pass metabolism reduced to 25% absolute bioavailability[1]
Protein binding 93%
Metabolism Hepatic glucuronidation and sulfoxidation
Half-life 10-19 hours[1][2]
Excretion Renal and biliary
Identifiers
CAS number 60-87-7 YesY
58-33-3 (hydrochloride)
ATC code D04AA10 R06AD02, R06AD05
PubChem CID 4926
DrugBank APRD00601
ChemSpider 4759 N
UNII FF28EJQ494 YesY
KEGG D00494 YesY
ChEBI CHEBI:8461 YesY
ChEMBL CHEMBL643 YesY
Chemical data
Formula C17H20N2S 
Mol. mass 284.42 g/mol
SMILES eMolecules & PubChem
 N(what is this?)  (verify)

Promethazine is a first-generation antihistamine of the phenothiazine family. The drug has anti-motion sickness, antiemetic, and anticholinergic effects, as well as a strong sedative effect and in some countries is prescribed for insomnia when benzodiazepines are contraindicated. It is available over-the-counter in the United Kingdom, Australia, Switzerland, and many other countries, but by prescription in the United States (brand names Phenergan, Promethegan, Romergan, Fargan, Farganesse, Prothiazine, Avomine, Atosil, Receptozine, Lergigan, and Sominex in the UK).[3]

Contents

[edit] Indications

[edit] Chemistry

Chemically, promethazine hydrochloride appears as a white to faint yellow crystalline powder that is practically odorless. Slow oxidation may occur upon prolonged exposure to air usually causing blue discoloration. Promethazine as the hydrochloride salt is freely soluble in water and somewhat soluble in alcohol. Promethazine is a chiral compound, occurring as a mixture of enantiomers (pictured).[7]

Promethazine, 10-(2-dimethylaminopropyl)phenothiazine, is synthesized by alkylating phenothiazine with 1-dimethylamino-2-propylchloride:[8][9]

Promethazine synthesis.png

[edit] Pharmacology

Promethazine is a phenothiazine derivative that is structurally different from the neuroleptic phenothiazines, with similar but different effects.[1] It acts primarily as a strong antagonist of the H1 receptor (antihistamine) and a moderate mACh receptor antagonist (anticholinergic),[1] and also has weak to moderate affinity for the 5-HT2A,[10] 5-HT2C,[10] D2,[11][12] and α1-adrenergic receptors,[13] where it acts as an antagonist at all sites as well.

Another notable property of promethazine is that it is a local anesthetic, via blockade of sodium channels.[13]

[edit] Side effects

Some common side effects include:

  • Tardive dyskinesia
  • Confusion in the elderly
  • Drowsiness, dizziness, fatigue, more rarely vertigo
  • Dry mouth
  • Respiratory depression in patients under age of 2 and in those with severely compromised pulmonal function
  • Constipation
  • Chest Discomfort/Pressure. (typically in cases when patient is already taking medication for high blood pressure)
  • Euphoria (very rare, except with high IV doses and/or coadministration with opioids/CNS depressants)
  • Akathisia [14]
  • Paresthesia
  • Short temper/Irritability

Extremely rare side effects include:

Because of potential for more severe side effects, this drug is on the list to avoid in the elderly. (See NCQA’s HEDIS Measure: Use of High Risk Medications in the Elderly).

[edit] Product liability lawsuit

In 2009, the U.S. Supreme Court ruled on a product liability case involving promethazine. Diana Levine, a woman suffering from a migraine, was administered Wyeth's Phenergan via IV push. The drug was injected improperly resulting in gangrene and subsequent amputation of her right forearm below the elbow. A state jury awarded her $6 million in punitive damages.

The case was appealed to the Supreme Court on grounds of federal preemption and substantive due process.[15] The Supreme Court upheld the lower courts' rulings stating that "Wyeth could have unilaterally added a stronger warning about IV-push administration" without acting in opposition to federal law.[16] In effect, this means that drug manufacturers can be held liable for injuries if warnings of potential adverse effects (approved by the U.S. Food and Drug Administration, "FDA") are deemed insufficient by state courts.

On September 9, 2009, the FDA made the decision that a black box warning for injection be put on promethazine stating the contraindication for subcutaneous administration. The preferred administrative route is intramuscular (IM) which reduces risk of surrounding muscle and tissue damage [17]

[edit] See also

  • Purple drank (a recreational drug concoction containing promethazine)

[edit] References

  1. ^ a b c d Strenkoski-Nix LC, Ermer J, DeCleene S, Cevallos W, Mayer PR (August 2000). "Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects". American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists 57 (16): 1499–505. PMID 10965395. http://www.ajhp.org/cgi/pmidlookup?view=long&pmid=10965395. 
  2. ^ Paton DM, Webster DR (1985). "Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)". Clinical Pharmacokinetics 10 (6): 477–97. PMID 2866055. http://content.wkhealth.com/linkback/openurl?issn=0312-5963&volume=10&issue=6&spage=477. 
  3. ^ RxList: Promethazine
  4. ^ a b c d e RxList Indications for Promethazine.
  5. ^ British National Formulary (March 2001). "4.6 Drugs used in nausea and Vertigo - Vomiting of pregnancy". BNF (45 ed.). .
  6. ^ [1].
  7. ^ http://www.rxlist.com/cgi/generic/phenergan.htm RxList: Promethazine Description
  8. ^ P. Charpentier, U.S. Patent 2,530,451 (1950)
  9. ^ S.B. Sidney, J.A. Nicholson, U.S. Patent 2,607,773 (1952)
  10. ^ a b Fiorella D, Rabin RA, Winter JC (October 1995). "The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis". Psychopharmacology 121 (3): 347–56. PMID 8584617. 
  11. ^ Seeman P, Watanabe M, Grigoriadis D, et al. (November 1985). "Dopamine D2 receptor binding sites for agonists. A tetrahedral model". Molecular Pharmacology 28 (5): 391–9. PMID 2932631. http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=2932631. 
  12. ^ Burt DR, Creese I, Snyder SH (April 1977). "Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain". Science 196 (4287): 326–8. doi:10.1126/science.847477. PMID 847477. http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=847477. 
  13. ^ a b Jagadish Prasad, P. (2010). Conceptual Pharmacology. Universities Press. pp. 295, 303, 598. ISBN 978-81-7371-679-9. http://books.google.com/books?id=s0e_FlM8LKYC&pg=PA295. Retrieved 27 November 2011. 
  14. ^ Cordingley Neurology
  15. ^ Liptak, Adam (2001-09-18). "Drug Label, Maimed Patient and Crucial Test for Justices". The New York Times. http://www.nytimes.com/2008/09/19/us/19scotus.html?n=Top/Reference/Times%20Topics/Organizations/S/Supreme%20Court&_r=1&adxnnl=1&oref=slogin&adxnnlx=1225505895-T2aivHeTdvJTT7b+uEsK1Q. Retrieved 2008-10-31. 
  16. ^ Stout, David (2009-03-04). "Drug Approval Is Not a Shield From Lawsuits, Justices Rule". The New York Times. http://www.nytimes.com/2009/03/05/washington/05scotus.html. Retrieved 2009-03-04. 
  17. ^ http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm182169.htm

[edit] External links


Personal tools
Namespaces
Variants
Actions
Navigation
Interaction
Toolbox
Print/export
Languages
Morty Proxy This is a proxified and sanitized view of the page, visit original site.